Adaptive Biotechnologies Corp (OQ:ADPT)

May 07, 2024 04:05 pm ET
Adaptive Biotechnologies Reports First Quarter 2024 Financial Results
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Apr 17, 2024 04:05 pm ET
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report...
Apr 02, 2024 04:05 pm ET
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a business update,...
Mar 27, 2024 08:30 am ET
Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will host a...
Feb 22, 2024 04:05 pm ET
Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be...
Feb 14, 2024 04:05 pm ET
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Jan 29, 2024 04:05 pm ET
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report...
Dec 27, 2023 04:05 pm ET
Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be...
Dec 09, 2023 08:30 am ET
Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced new data...
Dec 05, 2023 07:30 am ET
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, together with its collaborators...
Nov 09, 2023 04:05 pm ET
Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Nov 07, 2023 07:30 am ET
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year,...
Nov 02, 2023 04:05 pm ET
Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report...
Sep 26, 2023 09:31 am ET
Thinking about buying stock in Adaptive Biotechnologies, Liberty Media Corp Series A, Fisker, Transcode Therapeutics, or Nio Inc?
NEW YORK, Sept. 26, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADPT, LSXMA, FSR, RNAZ, and NIO.
Sep 13, 2023 07:30 am ET
Adaptive Announces Launch of Epic Integration for clonoSEQ®
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that clonoSEQ® is...
Aug 30, 2023 04:30 pm ET
Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Aug 02, 2023 04:05 pm ET
Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Jul 10, 2023 04:05 pm ET
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 2, 2023
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Jun 02, 2023 07:34 am ET
Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Canc
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in several oral...
May 24, 2023 04:05 pm ET
Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
May 12, 2023 08:00 am ET
Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
May 09, 2023 07:30 am ET
Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to detect and treat disease, today announced that the U.S. Food...
May 03, 2023 04:05 pm ET
Adaptive Biotechnologies Reports First Quarter 2023 Financial Results
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Apr 25, 2023 04:05 pm ET
Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Apr 12, 2023 07:30 am ET
Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it has entered...
Apr 06, 2023 04:05 pm ET
Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Feb 27, 2023 04:05 pm ET
Adaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare Conference
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Feb 14, 2023 04:05 pm ET
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Jan 23, 2023 04:05 pm ET
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Jan 10, 2023 08:00 am ET
Capella Space Raises $60M in Growth Equity from the United States Innovative Technology Fund to Expand Satellite Imaging Capacity and Meet Rapidly Growing Customer Demand
Leading provider of Earth observation data, utilizing Synthetic Aperture Radar (SAR), announces revenue tripled; brings on new CFO/COO, CISO and CHRO for next phase of growth
Dec 27, 2022 04:05 pm ET
Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Dec 21, 2022 07:36 am ET
Thinking about buying stock in HTG Molecular Diagnostics, 180 Life Sciences, Six Flags Entertainment, Under Armour, or Adaptive Biotechnologies?
NEW YORK, Dec. 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HTGM, ATNF, SIX, UAA, and ADPT.
Dec 10, 2022 10:00 am ET
Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced new data...
Dec 05, 2022 07:30 am ET
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), together with its collaborators, will present data from more than 30 abstracts showcasing the benefit of Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay in measuring minimal...
Dec 01, 2022 07:30 am ET
Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the launch of its...
Nov 21, 2022 04:05 pm ET
Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Nov 21, 2022 07:30 am ET
New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results
>- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and HealthTree Foundation, a...
Nov 03, 2022 04:05 pm ET
Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Oct 11, 2022 08:05 am ET
Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers 
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a partnership with...
Oct 05, 2022 04:05 pm ET
Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial...
Sep 12, 2022 08:30 am ET
Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it has entered into a...
Sep 02, 2022 08:00 am ET
Adaptive Biotechnologies to Participate in the Morgan Stanley Global Healthcare Conference
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Aug 03, 2022 04:05 pm ET
Adaptive Biotechnologies Reports Second Quarter 2022 Financial Results
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Jul 28, 2022 07:30 am ET
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring Minimal Residual Disease in Diffuse Large B-Cell Lymphoma
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that Palmetto GBA,...
Jul 08, 2022 04:05 pm ET
Adaptive Biotechnologies to Report Second Quarter of 2022 Financial Results on August 3, 2022
Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report...
Jun 15, 2022 07:30 am ET
Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the launch of...
Jun 02, 2022 04:10 pm ET
Adaptive Biotechnologies Included in Key Abstracts at ASCO 2022 Supporting the Role of the clonoSEQ® Assay as a Standard for MRD Assessment Technology
Data from Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in...
May 26, 2022 08:00 am ET
Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
May 04, 2022 04:05 pm ET
Adaptive Biotechnologies Reports First Quarter 2022 Financial Results
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
May 02, 2022 04:05 pm ET
Adaptive Biotechnologies to Present at the BofA Securities 2022 Healthcare Conference
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Apr 05, 2022 04:30 pm ET
Adaptive Biotechnologies to Report First Quarter Financial Results on May 4, 2022
Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report...
Mar 09, 2022 07:00 am ET
Adaptive Biotechnologies Appoints Tycho Peterson as Chief Financial Officer, Reorganizes and Streamlines Workforce to Drive Growth in Two Key Business Areas
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of...
Mar 02, 2022 04:05 pm ET
Adaptive Biotechnologies to Present at the 42nd Annual Cowen Healthcare Conference
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Feb 18, 2022 11:35 am ET
Adaptive Biotechnologies Announces New Data Demonstrating ImmunoSEQ® Technology Can Identify T-Cell Receptors Associated with Crohn’s Disease
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, presented data on T-cell receptor...
Feb 15, 2022 04:05 pm ET
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Feb 02, 2022 04:05 pm ET
Adaptive Biotechnologies to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Jan 24, 2022 04:05 pm ET
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2021 Financial Results on February 15, 2022
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report...
Jan 10, 2022 08:30 am ET
Adaptive Biotechnologies Announces Preliminary, Unaudited 2021 Revenue Results and CFO Transition
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) today reported preliminary, unaudited revenue for the year ended December 31, 2021. Total revenue for the year ended December 31, 2021 is estimated to be in the range of $153 million to $154...
Jan 04, 2022 04:05 pm ET
Updated: Adaptive Biotechnologies to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Dec 29, 2021 08:00 am ET
Adaptive Biotechnologies to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Dec 13, 2021 04:05 pm ET
Adaptive Biotechnologies Announces New Data Demonstrating the Benefit of Serial MRD Testing with the clonoSEQ® Assay in Patients with Blood Cancers at the 63rd ASH Annual Meeting
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced new data...
Dec 02, 2021 08:00 am ET
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts on Utility of clonoSEQ® in MRD Testing in Blood Cancer Patients at the 63rd ASH Annual Meeting
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, together with its collaborators...
Nov 11, 2021 05:52 pm ET
Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Disease (MRD) Assay, clonoSEQ® for Blood Cancer Patients
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that Palmetto GBA’s...
Nov 03, 2021 04:05 pm ET
Adaptive Biotechnologies Reports Third Quarter 2021 Financial Results
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Oct 06, 2021 04:05 pm ET
Adaptive Biotechnologies to Report Third Quarter Financial Results on November 3, 2021
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report...
Oct 02, 2021 01:15 pm ET
Adaptive Biotechnologies Presents New Data During IDWeek Demonstrating the Capability of Its Immune Medicine Platform to Distinguish Between SARS-CoV-2 Infection and Vaccine Response and Detect Lyme D
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, is presenting new data from three...
Sep 30, 2021 07:30 am ET
Adaptive Biotechnologies Launches Enhanced clonoSEQ® Assay Reports for Patients with Chronic Lymphocytic Leukemia, Now Featuring IGHV Mutation Status
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the launch of an...
Sep 21, 2021 04:05 pm ET
Adaptive Biotechnologies Announces Grand Opening of State-of-the-Art Headquarters and Expands Footprint in Seattle
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the opening of its...
Sep 16, 2021 08:03 am ET
Adaptive Biotechnologies to Present New SARS-CoV-2 Data from its Immune Medicine Platform During IDWeek 2021
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be presenting data from two...
Sep 07, 2021 05:15 pm ET
Adaptive Biotechnologies to Present at the Morgan Stanley Global Healthcare Conference
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be...
Aug 10, 2021 02:11 pm ET
Curebase, Adaptive Biotechnologies Announce Collaboration to Expand Clinical Study Access
SAN FRANCISCO and SEATTLE, Aug. 10, 2021 /PRNewswire/ -- Curebase, a company committed to democratizing access to clinical studies, and Adaptive Biotechnologies Corp. (Nasdaq: ADPT), a biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced an ongoing research collaboration to broaden patient participation in Adaptive's clinical studies. The initial two studies of the partnership involve Adaptive's T-Detect™ diagnostic test. T-Detect™ is under development for multiple diseases translating th
Aug 04, 2021 04:15 pm ET
Adaptive Biotechnologies Appoints Nitin Sood as Chief Commercial Officer
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of...
Aug 04, 2021 04:05 pm ET
Adaptive Biotechnologies Reports Second Quarter 2021 Financial Results
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Jul 12, 2021 04:05 pm ET
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 4, 2021
Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report...
Jun 09, 2021 07:15 am ET
New Study Published in Nature Provides Further Evidence that COVID-19 Vaccine Induced T-Cell Response Targets Known SARS-CoV-2 Variants of Concern
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that immunoSEQ®...
Jun 03, 2021 07:30 am ET
Adaptive Biotechnologies Included in More than 20 Abstracts at ASCO and EHA 2021 Highlighting Expanding Use Cases for MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in more than 20...
May 20, 2021 04:05 pm ET
Adaptive Biotechnologies to Participate in Upcoming June 2021 Investor Conferences
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be...
May 05, 2021 04:05 pm ET
Adaptive Biotechnologies Reports First Quarter 2021 Financial Results
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Apr 27, 2021 04:05 pm ET
Adaptive Biotechnologies to Present at the BofA Securities 2021 Virtual Healthcare Conference
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be...
Apr 12, 2021 04:05 pm ET
Adaptive Biotechnologies to Report First Quarter Financial Results on May 5, 2021
Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report...
Mar 17, 2021 04:05 pm ET
Adaptive Biotechnologies Strengthens Expertise and Diversity of Board of Directors with Appointments of Leslie Trigg and Katey Owen
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointments...
Mar 05, 2021 06:44 pm ET
Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Detect™ COVID to Confirm Recent or Prior COVID-19 Infection
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that the U.S. Food...
Feb 25, 2021 04:05 pm ET
Adaptive Biotechnologies to Present at the Cowen 41st Annual Healthcare Conference
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be...
Feb 24, 2021 04:05 pm ET
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2020 Financial Results
Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Feb 23, 2021 09:15 am ET
Adaptive Biotechnologies Expands Collaboration with Labcorp to Increase Access to Growing Research and Clinical Diagnostic Portfolio
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced an expansion of...
Feb 23, 2021 07:30 am ET
Adaptive Biotechnologies Launches T-Detect™ COVID, First Clinical T-Cell Based Test for Patients to Confirm Recent or Prior COVID-19 Infection
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the launch of...
Feb 02, 2021 04:05 pm ET
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report...
Jan 11, 2021 04:01 pm ET
Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a translational...
Dec 30, 2020 04:30 pm ET
Adaptive Biotechnologies to Present at the 39th Annual J.P. Morgan Healthcare Conference
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Dec 06, 2020 10:00 am ET
Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced new real-world...
Nov 23, 2020 08:00 am ET
Adaptive Biotechnologies and Collaborators to Present Data from More Than 35 Abstracts at ASH 2020 Highlighting Clinical Relevance of MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, together with its collaborators...
Nov 13, 2020 08:00 am ET
Preliminary Data from Real-World Study Demonstrate T-cell Testing Outperforms Antibody Testing in Identifying Past SARS-CoV-2 Infections
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its T-Detect™...
Nov 10, 2020 04:12 pm ET
Adaptive Biotechnologies Announces Collaboration with GSK to Measure Minimal Residual Disease with clonoSEQ® Assay Across its Hematology and Oncology Portfolio
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a collaboration...
Nov 10, 2020 04:10 pm ET
Adaptive Biotechnologies Reports Third Quarter 2020 Financial Results
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Oct 13, 2020 04:05 pm ET
Adaptive Biotechnologies to Report Third Quarter Financial Results on November 10, 2020
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report...
Sep 01, 2020 04:03 pm ET
Adaptive Biotechnologies to Present at the Morgan Stanley 2020 Healthcare Conference
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be...
Aug 10, 2020 04:05 pm ET
Adaptive Biotechnologies Reports Second Quarter 2020 Financial Results
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Aug 10, 2020 08:05 am ET
Adaptive Biotechnologies to Present at the UBS Genomics 2.0 and Medtech Innovations Summit
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be...
Aug 06, 2020 09:24 am ET
Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today received clearance from the...
Aug 04, 2020 09:30 am ET
Adaptive Biotechnologies Launches immunoSEQ T-MAP COVID, First Molecular T Cell Monitoring Tool for SARS-CoV-2
Adaptive Biotechnologies (Nasdaq: ADPT) announced today the launch of immunoSEQ® T-MAP™ COVID, a proprietary research product and data analysis service to accurately and reproducibly measure the T-cell immune response to vaccines in development and...
Jul 28, 2020 06:04 pm ET
Adaptive Biotechnologies Launches National Clinical Trial to Develop Novel T-Cell Based Diagnostic for Lyme Disease
Adaptive Biotechnologies Corp. (Nasdaq: ADPT) announced today the launch of ImmuneSense Lyme™, a research study to inform the development of an improved test to detect Lyme disease in the early stages of an infection, when the disease is most...
Jul 15, 2020 07:47 pm ET
Adaptive Biotechnologies Announces Pricing of Public Offering of Common Stock
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pricing of an...
Jul 14, 2020 04:44 pm ET
Adaptive Biotechnologies Announces Proposed Public Offering of Common Stock
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the commencement...
Jul 09, 2020 08:05 am ET
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 10, 2020
Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report...
Jun 11, 2020 09:00 am ET
Adaptive Biotechnologies and Microsoft launch groundbreaking ImmuneCODE database to share populationwide immune response to the COVID-19 virus
SEATTLE and REDMOND, Wash., June 11, 2020 /PRNewswire/ -- Adaptive Biotechnologies Corp. (Nasdaq: ADPT) on Thursday launched ImmuneCODE with Microsoft Corp. (Nasdaq: MSFT) to begin sharing one of the largest, most detailed views of the immune response to COVID-19 in real time based on de-identified data generated from thousands of COVID-19 blood samples from patients around the globe. The open database contains detailed information on the extraordinarily diverse set of T cells shown to specifically recognize unique features of the COVID-19 virus, called antigens, with unprecedented speed and
Jun 08, 2020 04:03 pm ET
UPDATE – Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
This release was previously disseminated on May 27, 2020 at 16:03 ET. The date and time details for the conferences have been updated. The complete and corrected release follows. Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial...
May 27, 2020 04:03 pm ET
Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will...
May 12, 2020 04:03 pm ET
Adaptive Biotechnologies Reports First Quarter 2020 Financial Results
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
May 06, 2020 09:31 am ET
Thinking about trading stocks or options in Nutanix, Pfizer, Mercadolibre, Adaptive Biotechnologies, or Microsoft?
NEW YORK, May 6, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NTNX, PFE, MELI, ADPT, and MSFT.
May 06, 2020 08:00 am ET
Adaptive Biotechnologies to Present at the BofA Securities 2020 Healthcare Conference
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be...
May 05, 2020 12:00 pm ET
Adaptive Biotechnologies and Microsoft launch virtual ImmuneRACE study to inform novel COVID-19 diagnostics to address unmet needs in testing
SEATTLE and REDMOND, Wash., May 5, 2020 /PRNewswire/ -- Adaptive Biotechnologies Corp. (Nasdaq: ADPT) announced on Tuesday it has begun enrolling a virtual clinical study, ImmuneRACE, as part of a broader effort it has undertaken with Microsoft Corp. (Nasdaq: MSFT) to rapidly map and measure the immune response to the COVID-19 virus to inform improved diagnostics to fulfill the need for more reliable testing. The study calls for 1,000 participants in select U.S. metropolitan areas impacted by COVID-19. De-identified data will be made freely available to public health officials, academia and
Apr 28, 2020 06:00 am ET
Sweetwater Private Equity recognizes Adaptive Biotechnologies Corp. and its CEO Chad Robins for leadership during COVID-19 crisis
SAN DIEGO, April 28, 2020 /PRNewswire/ -- Sweetwater Investment Management ("Sweetwater" or "Sweetwater Private Equity" (dba)) announced during their recent annual investor meeting the selection of Chad Robins, CEO of Adaptive Biotechnologies Corp. (Nasdaq: ADPT), as the Sweetwater Leadership and Innovation Award recipient.  Each year Sweetwater selects one of the most innovative and inspiring leaders from its portfolio companies. "Mr. Robins is one of the most brilliant leaders of our time," said Mr. James Gamett, Founder & Managing Partner of Sweetwater. "As CEO of Adaptive Biotechnolo
Apr 27, 2020 04:03 pm ET
Adaptive Biotechnologies to Report First Quarter Financial Results on May 12, 2020
Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report...
Apr 09, 2020 07:45 pm ET
Adaptive Biotechnologies Expands Executive Leadership Team to Support Development and Commercialization of Clinical Products, including immunoSEQ Dx
Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the addition of two prominent...
Apr 07, 2020 08:35 pm ET
Amgen And Adaptive Biotechnologies To Participate In Webinar On COVID-19 Strategic Collaboration
THOUSAND OAKS, Calif., and SEATTLE, April 7, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies Corporation (NASDAQ:ADPT) will participate in a webinar hosted by Bernstein on Thursday, April 9 at 8 a.m. PT (11 a.m. ET) where David M. Reese, M.D., executive vice president of Research and Development at Amgen and Harlan Robins, PhD, chief scientific officer and co-founder at Adaptive, will discuss the companies' strategic collaboration to develop a therapeutic to prevent or treat COVID-19. 
Apr 02, 2020 09:00 am ET
Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19
THOUSAND OAKS, Calif., and SEATTLE, April 2, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies (NASDAQ:ADPT) today announced a collaboration aimed at helping address the COVID-19 pandemic. The companies will combine expertise to discover and develop fully human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19. The mutually exclusive collaboration brings together Adaptive's proprietary immune medicine platform for the identification of virus-neutralizing antibodies with Amgen's expertise in immunology and novel antibody therapy developm
Mar 20, 2020 01:02 pm ET
Adaptive Biotechnologies and Microsoft expand partnership to decode COVID-19 immune response and provide open data access
SEATTLE and REDMOND, Wash., March 20, 2020 /PRNewswire/ -- Adaptive Biotechnologies Corp. (Nasdaq: ADPT) and Microsoft Corp. (Nasdaq: MSFT) on Friday announced they will leverage their existing partnership mapping population-wide adaptive immune responses to diseases at scale to study COVID-19. Finding the relevant immune response signature may advance solutions to diagnose, treat and prevent the disease, augmenting existing research efforts that primarily focus on the biology of the virus. These data will be made freely available to any researcher, public health official or organization aro
Feb 26, 2020 04:05 pm ET
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2019 Financial Results
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...
Feb 19, 2020 04:05 pm ET
Adaptive Biotechnologies to Present at the 40th Annual Cowen Health Care Conference
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the company will...
Feb 12, 2020 04:05 pm ET
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that it will...
Jan 23, 2020 08:53 pm ET
Adaptive Announces Pricing of Public Offering of Common Stock
Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pricing of its...
Jan 21, 2020 04:39 pm ET
Adaptive Announces Proposed Public Offering of Common Stock
Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the commencement of...
Jan 21, 2020 04:02 pm ET
Adaptive Announces Preliminary Unaudited Revenue for Full Year 2019
Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today preliminary...
Jan 13, 2020 07:30 am ET
Adaptive and Genentech Partner to Use clonoSEQ® Assay to Measure Minimal Residual Disease as a Primary Endpoint in Phase III Study of Chronic Lymphocytic Leukemia Patients
Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year,...
Jan 08, 2020 07:30 am ET
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring MRD in Patients With Chronic Lymphocytic Leukemia
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that Palmetto GBA,...
Dec 30, 2019 04:05 pm ET
Adaptive Biotechnologies to Present at the 38th Annual J.P. Morgan Healthcare Conference
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), today announced the company will be participating in the upcoming 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Adaptive’s management is...
Dec 09, 2019 08:00 am ET
Adaptive and AbbVie Partner Across Multiple Myeloma Trials to Measure Minimal Residual Disease Using the clonoSEQ® Assay
Adaptive Biotechnologies Corporation (Nasdaq:ADPT) today announced a multi-year, global collaboration agreement with AbbVie (NYSE: ABBV) to utilize Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease...
Dec 04, 2019 04:30 pm ET
Adaptive Biotechnologies and Collaborators to Present Data from More Than 25 clonoSEQ® Abstracts at ASH 2019 Demonstrating Clinical Relevance of Standardized, Accurate MRD Testing for Blood Cancer Pat
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and its collaborators will present...
Nov 12, 2019 04:05 pm ET
Adaptive Biotechnologies Corporation Reports Third Quarter 2019 Financial Results
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) today reported financial results for the quarter ended September 30, 2019. “During the third quarter, we continued to make strong progress across our existing...
Oct 29, 2019 04:05 pm ET
Adaptive Biotechnologies to Report Third Quarter Financial Results on November 12, 2019
Adaptive Biotechnologies (Nasdaq: ADPT) today announced that it will report financial results for the third quarter of 2019 after market close on Tuesday, November 12, 2019. Company management will host a corresponding conference call, beginning at...
Sep 24, 2019 08:00 am ET
Adaptive Biotechnologies Enters Partnership with Illumina to Develop Distributable IVD Test Kits for clonoSEQ and immunoSEQ Dx
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a partnership with...
Sep 17, 2019 08:00 am ET
Adaptive Biotechnologies Enters Partnership for Use Of clonoSEQ® as Preferred MRD Test for Drug Development Across Amgen’s Hematology Franchise
Adaptive Biotechnologies Corporation (Nasdaq:ADPT) today announced it has entered into a global agreement with Amgen for the use of Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease (MRD) across...
Aug 13, 2019 04:05 pm ET
Adaptive Biotechnologies Corporation Reports Second Quarter 2019 Financial Results
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) today reported financial results for the quarter ended June 30, 2019. “At Adaptive, we are translating the genetics of the adaptive immune system into clinical...
Aug 07, 2019 08:30 am ET
Adaptive Biotechnologies Executes Lease for New 100,000 Square Foot Corporate Headquarters, Tripling its Footprint in Seattle’s Growing Biotech Hub
Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune system with the goal of developing personalized diagnostics and therapeutics to improve...
Aug 01, 2019 04:15 pm ET
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 13, 2019
Adaptive Biotechnologies (Nasdaq: ADPT) today announced that it will report financial results for the second quarter of 2019 after market close on Tuesday, August 13, 2019. Company management will host a corresponding conference call, beginning at...
Jul 31, 2019 04:15 pm ET
Adaptive Biotechnologies Receives New York State CLEP Approval for clonoSEQ to Detect and Monitor Minimal Residual Disease (MRD) in Patients with Certain Blood Cancers
Adaptive Biotechnologies Corporation (Nasdaq:ADPT) (“Adaptive”), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune system with the goal of developing personalized diagnostics and therapeutics...
Jul 01, 2019 04:05 pm ET
Adaptive Biotechnologies Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Adaptive Biotechnologies Corporation (Nasdaq:ADPT) (“Adaptive”), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune system to develop personalized diagnostics and therapeutics to improve...
Jun 27, 2019 07:00 am ET
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) to Ring The Nasdaq Stock Market Opening Bell
What: Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune system to develop personalized diagnostics and therapeutics to improve patient...
Jun 26, 2019 07:57 pm ET
Adaptive Biotechnologies Announces Pricing of Initial Public Offering
Adaptive Biotechnologies Corporation (Nasdaq:ADPT) (“Adaptive”), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune system to develop personalized diagnostics and therapeutics to improve...
May 03, 2017 02:08 pm ET
DEADLINE ALERT: Brower Piven Reminds Investors Of The Upcoming Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Adeptus Health Inc. (NYSE:
STEVENSON, Md., May 03, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Texas on behalf of purchasers of Adeptus Health Inc. (NYSE:ADPT) (“Adeptus” or the “Company”) securities during the period between April 29, 2016 and March 1, 2017, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until May 9, 2017 to seek appointment as lead plaintiff....
May 01, 2017 04:11 pm ET
ADPT EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Adeptus Health Inc. and a Lead Plaintiff Deadline of May 9, 2017
NEW YORK, May 01, 2017 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Texas, Tyler Division on behalf of investors who purchased Adeptus Health Inc. ("Adeptus Health Inc.") (NYSE:ADPT) securities between April 29, 2016 and March 1, 2017....
Apr 28, 2017 06:41 pm ET
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Adeptus Health Inc. - ADPT
NEW YORK, April 28, 2017 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Adeptus Health Inc. securities (NYSE: ADPT) from April 29, 2016 through March 1, 2017, both dates inclusive (the "Class Period"). The lawsuit seeks to recover damages for Adeptus investors under the federal securities laws.
Apr 27, 2017 10:41 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Adeptus Health, Inc. and Certain Officers - ADPT
NEW YORK, April 27, 2017 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Adeptus Health, Inc. ("Adeptus" or the "Company") (NYSE: ADPT) and certain of its officers.   The class action, filed in United States District Court, Eastern District of Texas, Tyler Division, and docketed under 17-cv-00241, is on behalf of a class consisting of investors who purchased or otherwise acquired Adeptus securities, seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934.
Apr 20, 2017 07:07 pm ET
Applied Optoelectronics Set to Join S&P SmallCap 600
NEW YORK, April 20, 2017 /PRNewswire/ -- Applied Optoelectronics Inc. (NASD: AAOI) will replace Adeptus Health Inc. (NYSE: ADPT) in the S&P SmallCap 600, effective prior to the open on Tuesday, April 25. Adeptus Health has filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code to pursue a plan of reorganization and has been halted by the NYSE effective before the market open today.
Apr 19, 2017 07:00 pm ET
Adeptus Health and Deerfield Join Forces to Enable High Quality Emergency Care
NEW YORK, April 19, 2017 /PRNewswire/ -- Deerfield Management announced its plan to acquire Adeptus Health with a long-term commitment to the delivery of high quality, efficient emergency care.  Deerfield is a 23 year-old firm focused on advancing healthcare through investment, information, and philanthropy.  With over $8 billion in assets, and industry leading investment, operations, and market research teams, Deerfield brings to Adeptus highly relevant expertise in addition to expansion capital. 
Apr 19, 2017 06:42 pm ET
Adeptus Health and Deerfield Collaborate on Comprehensive Financial Restructuring Plan
LEWISVILLE, Texas, April 19, 2017 /PRNewswire/ -- Adeptus Health Inc. (NYSE: ADPT), the largest operator of freestanding emergency rooms in the U.S., today announced that it has collaborated with Deerfield Management Company ("Deerfield") and certain of its other creditors on the terms of a comprehensive financial restructuring plan that is expected to significantly reduce the outstanding debt under the Company's existing credit facility and better position Adeptus for long-term success.
Apr 18, 2017 04:00 pm ET
Safirstein Metcalf LLP Announces That A Class Action Lawsuit Has Been Filed Against Adeptus Health, Inc. – ADPT
NEW YORK, April 18, 2017 (GLOBE NEWSWIRE) -- Safirstein Metcalf LLP announces that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of Texas on behalf of all persons or entities who purchased or otherwise acquired securities of Adeptus Health, Inc. ("Adeptus Health”) (NASDAQ:ADPT) between April 29, 2016 and March 1, 2017. ...
Apr 13, 2017 02:00 pm ET
The Klein Law Firm Announces a Class Action Filed on Behalf of Adeptus Health Inc. Shareholders and Lead Plaintiff Deadline of May 9, 2017
NEW YORK, April 13, 2017 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Adeptus Health Inc. (NYSE:ADPT) who purchased shares between April 29, 2016 and March 1, 2017. The action, which was filed in the United States District Court for the Eastern District of Texas, Tyler Division, alleges that the Company violated federal securities laws....
Apr 12, 2017 01:30 pm ET
Rosen Law Firm Reminds Adeptus Health Inc. Investors of Important Deadline in Class Action Filed by Firm – ADPT
NEW YORK, April 12, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Adeptus Health Inc. securities (NYSE:ADPT) from April 29, 2016 through March 1, 2017, both dates inclusive (the “Class Period”) of the important May 9, 2017 lead plaintiff deadline in the class action filed by the firm. The lawsuit seeks to recover damages for Adeptus investors under the federal securities laws....
Apr 03, 2017 04:27 pm ET
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Adeptus Health Inc. (ADPT) To Contact Brower Piven Before The Lead Plaintiff Deadline In C
STEVENSON, Md. , April 03, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Texas on behalf of purchasers of Adeptus Health Inc. (NYSE:ADPT) (“Adeptus” or the “Company”) securities during the period between April 29, 2016 and March 1, 2017, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until May 9, 2017 to seek appointment as lead plaintiff....
Mar 23, 2017 05:15 pm ET
Adeptus Health Inc. Receives NYSE Notice Regarding Late Form 10-K Filing
LEWISVILLE, Texas, March 23, 2017 /PRNewswire/ -- Adeptus Health Inc. (NYSE: ADPT) (the "Company") announced today that, as a result of its failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2016 (the "Form 10-K"), it has received a notice from the New York Stock Exchange (the "NYSE") that the Company is not in compliance with the NYSE's continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual.
Mar 14, 2017 04:05 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adeptus Health, Inc. - ADPT
NEW YORK, March 14, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Adeptus Health, Inc. ("Adeptus Health" or the "Company") (NYSE: ADPT) (ISIN: US0068551003). Investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Mar 14, 2017 11:10 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Adeptus Health Inc. (ADPT) & Lead Plaintiff Deadline: May 9, 2017
NEW YORK, March 14, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Adeptus Health Inc. ("Adeptus" or the "Company") (NYSE: ADPT) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Adeptus securities April 29, 2016 through March 1, 2017, both dates inclusive (the "Class Period"). Investors are encouraged to learn more about this case by visiting the firm's site: http://www.bgandg.com/adpt.
Mar 02, 2017 03:37 pm ET
Adeptus Health Inc. Investigated For Securities Fraud By Block & Leviton After Delaying Its Year-End Financial Results
BOSTON, March 2, 2017 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Adeptus Health Inc. ("Adeptus" or the "Company") (NYSE: ADPT) and certain of its officers and directors violated federal securities laws following the Company's announcement that it will not timely file it's 2016 financial results due to "material weaknesses" in its financial reporting.
Dec 23, 2016 09:30 am ET
Dec 22, 2016 03:55 pm ET
The Saxena White P.A. Securities Fraud Class Action Against Adeptus Health Inc. With Expanded Class Period is Now Pending in the Tyler Division of the Eastern District of Texas
Saxena White P.A. has filed a securities fraud class action lawsuit that is now pending in the Tyler Division of the United States District Court for the Eastern District of Texas against Adeptus Health Inc. ("Adeptus Health" or the "Company")...
Dec 19, 2016 12:33 pm ET
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Adeptus Health Inc. - ADPT
NEW YORK, Dec. 19, 2016 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Adeptus Health securities (NYSE: ADPT): (1) from April 23, 2015 through November 16, 2015, both dates inclusive; and/or (2) pursuant and/or traceable to Adeptus Health's secondary public offering on or about July 31, 2015. The lawsuit seeks to recover damages for Adeptus Health investors under the federal securities laws.
Dec 09, 2016 10:50 pm ET
ADEPTUS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ad
NEW ORLEANS, Dec. 09, 2016 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 26, 2016 to file lead plaintiff applications in a securities class action lawsuit against Adeptus Health Inc. (NYSE:ADPT), if they purchased Adeptus’ Class A shares between June 25, 2014 and November 1, 2016, inclusive (the “Class Period”), or if they purchased Adeptus’ common stock pursuant to its initial public offering on June 25, 2014, or its secondary public offerings on or abou...
Dec 07, 2016 11:00 am ET
ADPT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Adeptus Health Inc. and a Lead Plaintiff Deadline of December 27, 2016
NEW YORK, Dec. 7, 2016 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of Texas on behalf of investors who purchased Adeptus Health Inc. (NYSE: ADPT) securities pursuant to the Company's secondary public offering on or about July 31, 2015, and purchasers of common shares between April 23, 2015 and November 16, 2015.
Dec 02, 2016 06:20 pm ET
Rosen Law Firm Reminds Adeptus Health Inc. Investors of Important Deadline in Class Action - ADPT
NEW YORK, Dec. 02, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Adeptus Health securities (NYSE:ADPT): (1) from April 23, 2015 through November 16, 2015, both dates inclusive; and/or (2) pursuant and/or traceable to Adeptus Health’s secondary public offering on or about July 31, 2015 of the important December 27, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Adeptus Health investors under the federal securities laws....
Nov 29, 2016 08:00 am ET
Adeptus Health Receives 2016 Press Ganey Guardian of Excellence Award for Outstanding Performance in Patient Experience for Fourth Consecutive Year
LEWISVILLE, Texas, Nov. 29, 2016 /PRNewswire/ -- Adeptus Health (NYSE: ADPT) is proud to announce that its network of freestanding emergency rooms has been named a 2016 Guardian of Excellence Award® winner by Press Ganey. The Guardian of Excellence Award recognizes top-performing health care organizations that have consistently achieved the 95th percentile or above of performance in patient experience, and Adeptus Health has maintained this rating for the last four years.
Nov 27, 2016 06:00 am ET
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Adeptus Health Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Ac
STEVENSON, Md., Nov. 27, 2016 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Texas on behalf of purchasers of Adeptus Health Inc. (NYSE:ADPT) (Adeptus or the “Company”) shares pursuant and/or traceable to the Company’s secondary public offering (the “SPO”) on or about July 31, 2015, or purchasers of common shares between April 23, 2015 and November 16, 2015, inclusive (the “Class Period”).  Investors who wish to become...
Nov 25, 2016 10:07 pm ET
Adeptus Shareholder Alert By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ad
NEW ORLEANS, Nov. 25, 2016 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 26, 2016 to file lead plaintiff applications in a securities class action lawsuit against Adeptus Health Inc. (NYSE: ADPT), if they purchased Adeptus' Class A shares between June 25, 2014 and November 16, 2015, inclusive (the "Class Period"), or if they purchased Adeptus' common stock pursuant to its initial public offering on June 25, 2014, or its secondary public offerings on or about Ma
Nov 17, 2016 03:40 pm ET
Saxena White P.A. Files Securities Fraud Class Action Against Adeptus Health Inc. With Expanded Class Period
Saxena White P.A. has filed a securities fraud class action lawsuit in the United States District Court for the Eastern District of Texas against Adeptus Health Inc. ("Adeptus Health" or the "Company") (NYSE: ADPT) and certain of the Company's...
Nov 16, 2016 02:08 pm ET
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Adeptus Health Inc. - ADPT
NEW YORK, Nov. 16, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Adeptus Health securities (NYSE:ADPT): (1) from April 23, 2015 through November 16, 2015, both dates inclusive; and/or (2) pursuant and/or traceable to Adeptus Health’s secondary public offering on or about July 31, 2015. The lawsuit seeks to recover damages for Adeptus Health investors under the federal securities laws....
Nov 11, 2016 10:07 pm ET
ADEPTUS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ad
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 26, 2016 to file lead plaintiff applications in a securities class action lawsuit...
Nov 09, 2016 02:39 pm ET
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Adeptus Health Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 27, 2016 -- ADPT
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Adeptus Health Inc. ("Adeptus") (NYSE: ADPT) pursuant and/or traceable to the Company's secondary...
Nov 08, 2016 04:48 pm ET
IMPORTANT NOTICE TO SHAREHOLDERS:  Brower Piven Notifies Shareholders of Securities Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Adeptus Healt
STEVENSON, Md., Nov. 08, 2016 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Texas on behalf of purchasers of Adeptus Health Inc. (NYSE:ADPT) (Adeptus or the “Company”) shares pursuant and/or traceable to the Company’s secondary public offering (the “SPO”) on or about July 31, 2015, or purchasers of common shares between April 23, 2015 and November 16, 2015, inclusive (the “Class Period”).  Investors who wish to become...
Nov 08, 2016 06:30 am ET
Adeptus Health Announces Appointment of Gregory W. Scott as Interim Chief Executive Officer
LEWISVILLE, Texas, Nov. 8, 2016 /PRNewswire/ -- Adeptus Health Inc. (NYSE: ADPT), the largest operator of freestanding emergency rooms in the U.S., today announced that Gregory W. Scott, who was recently appointed Chairman of the Board of Directors, has been appointed interim Chief Executive Officer effective immediately, following the resignation of Thomas S. Hall. In September, Mr. Hall informed the Board of his plans to retire by mid-2017. Given the recent challenges at the Company, Mr. Hall decided to accelerate his retirement.
Nov 03, 2016 10:10 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Adeptus Health Inc. (ADPT) & Lead Plaintiff Deadline: December 27, 2016
NEW YORK, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Adeptus Health Inc. (“Adeptus” or the “Company”) (NYSE:ADPT) and certain of its officers. This case is on behalf of shareholders who purchased or otherwise acquired shares pursuant and/or traceable to the Company’s secondary public offering (the “SPO”) on or about July 31, 2015, or purchasers of common shares between April 23, 2015 and November 16, 2015, inclusive (the “Class Period”)....
Nov 03, 2016 09:30 am ET
ADEPTUS HEALTH INVESTOR ALERT: Hagens Berman Alerts Adeptus Health Inc. Investors to Securities Class Action Lawsuit and Lead Plaintiff Deadline
SAN FRANCISCO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in Adeptus Health Inc. (NYSE:ADPT) to the securities class action lawsuit filed in the U.S. District Court for the Eastern District of Texas and the Lead Plaintiff deadline of December 27, 2016....
Nov 02, 2016 08:35 pm ET
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Adeptus Health Inc.
WAYNE, Pa., Nov. 2, 2016 /PRNewswire/ -- Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in United States District Court for the Eastern District of Texas on behalf of purchasers of Adeptus Health Inc. ("Adeptus Health" or the "Company") (NYSE: ADPT) Class A common shares (hereinafter the "common shares" or "common stock") pursuant and/or traceable to the Company's secondary public offering (the "SPO") on or about July 31, 2015, seeking to pursue remedies under the Securities Act of 1933 (the "Securities Act"), as well as purchasers of the Company's common share
Nov 02, 2016 08:48 am ET
ADEPTUS (ADPT) Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Adeptus Health Inc.; Investors Encouraged to Contact Firm
SAN DIEGO, Nov. 2, 2016 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP has commenced an investigation of Adeptus Health Inc. (NYSE: ADPT) concerning possible violations of federal securities laws. Adeptus Health owns and operates a network of independent freestanding emergency rooms in the United States.
Nov 01, 2016 05:15 pm ET
Adeptus Health Announces Appointment Of Gregory W. Scott As Chairman Of The Board Of Directors
LEWISVILLE, Texas, Nov. 1, 2016 /PRNewswire/ -- Adeptus Health Inc. (NYSE: ADPT), the largest operator of freestanding emergency rooms in the U.S., today announced that its Board of Directors has appointed Gregory W. Scott, Adeptus Director since 2013, as Chairman, effective immediately. Mr. Scott succeeds Thomas S. Hall as Chairman. This is an initial step given Mr. Hall's previously announced retirement.
Nov 01, 2016 05:15 pm ET
Adeptus Health Reports Third Quarter 2016 Results
LEWISVILLE, Texas, Nov. 1, 2016 /PRNewswire/ -- Adeptus Health Inc. (NYSE: ADPT) ("ADPT" or the "Company"), the largest operator of freestanding emergency rooms in the U.S., announced its results for the third quarter ended September 30, 2016. All comparisons included in this release are for the same period in the prior year, unless otherwise noted. See "Non-GAAP Financial Measures Description and Reconciliation" for further information related to systemwide revenue, Adjusted EBITDA and Adjusted earnings per share.
Nov 01, 2016 12:38 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adeptus Health, Inc. - ADPT
NEW YORK, Nov. 1, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Adeptus Health, Inc. ("Adeptus Health" or the "Company") (NYSE: ADPT) (ISIN: US0068551003). Investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Nov 01, 2016 11:15 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Adeptus Health Inc. (ADPT) & Lead Plaintiff Deadline: December 27, 2016
NEW YORK, Nov. 1, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Adeptus Health Inc. ("Adeptus" or the "Company") (NYSE: ADPT) and certain of its officers. This case is on behalf of shareholders who purchased or otherwise acquired shares pursuant and/or traceable to the Company's secondary public offering (the "SPO") on or about July 31, 2015, or purchasers of common shares between April 23, 2015 and November 16, 2015, inclusive (the "Class Period")
Nov 01, 2016 07:45 am ET
Adeptus Health Reschedules Third Quarter 2016 Earnings
LEWISVILLE, Texas, Nov. 1, 2016 /PRNewswire/ -- Adeptus Health Inc. (NYSE: ADPT) ("ADPT" or the "Company"), announced today that it is rescheduling its third quarter 2016 earnings release until after the market close today and will host a rescheduled conference call at 5:00 p.m. (ET), originally scheduled to be held at 10:00 a.m. (ET) on Tuesday, November 1, 2016.
Oct 31, 2016 04:44 pm ET
Harwood Feffer LLP Announces Investigation of Adeptus Health Inc.
NEW YORK, Oct. 31, 2016 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Adeptus Health Inc. ("Adeptus" or the "Company") (NYSE: ADPT), concerning whether the board has breached its fiduciary duties to shareholders.
Oct 31, 2016 03:08 pm ET
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Adeptus Health, Inc.
On October 27, 2016, a class action lawsuit was filed in the United States District Court for the Eastern District of Texas against Adeptus Health, Inc. (NYSE: ADPT). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is April 23, 2015 through November 16, 2015.
Oct 31, 2016 12:38 pm ET
Oct 28, 2016 10:07 pm ET
ADEPTUS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ad
NEW ORLEANS, Oct. 28, 2016 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 26, 2016 to file lead plaintiff applications in a securities class action lawsuit against Adeptus Health Inc. (NYSE:ADPT), if they purchased the Company’s Class A common shares pursuant to the July 31, 2015 secondary public offering or between April 23, 2015 and November 16, 2015, inclusive (the “Class Period”).  This action is pending in the United States District Court for the East...
Oct 28, 2016 08:00 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Adeptus Health Inc. (ADPT)
NEW YORK, Oct. 28, 2016 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Adeptus Health Inc. (“Adeptus” or the “Company”) (NYSE:ADPT) in the United States District Court for the Eastern District of Texas on behalf of purchasers of common stock of Adeptus pursuant and/or traceable to the Company’s secondary public offering (the “SPO”) on or about July 31, 2015, or purchasers of common shares between April 23, 2015 and November 16, 2015, inclusive (the “Class Period”)....
Oct 28, 2016 12:20 pm ET
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Adeptus Health Inc. To Contact The Firm Before Lead Plaintiff Deadline
NEW YORK, Oct. 28, 2016 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Adeptus Health Inc. (“Adeptus” or the “Company”) (NYSE:ADPT) of the December 27, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers....
Oct 27, 2016 07:43 pm ET
Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Adeptus Health Inc.
NEW YORK, Oct. 27, 2016 /PRNewswire-USNewswire/ -- Robbins Geller Rudman & Dowd LLP ("Robbins Geller") (http://www.rgrdlaw.com/cases/adeptus/) today announced that a class action has been commenced by an institutional investor on behalf of purchasers of Adeptus Health Inc. ("Adeptus Health" or the "Company") (NYSE: ADPT) Class A common shares (hereinafter the "common shares" or "common stock") pursuant and/or traceable to the Company's secondary public offering (the "SPO") on or about July 31, 2015, seeking to pursue remedies under the Securities Act of 1933 (the "Securities Act"), as we
Oct 20, 2016 06:32 pm ET
Adeptus Health to Announce Third Quarter 2016 Financial Results
LEWISVILLE, Texas, Oct. 20, 2016 /PRNewswire/ -- Adeptus Health Inc. (NYSE: ADPT), the largest operator of freestanding emergency rooms in the U.S., today announced that it will release its third quarter 2016 financial results pre-market on Tuesday, November 1, 2016.
Sep 07, 2016 07:45 am ET
Adeptus Health Announces Planned Retirement of Thomas S. Hall
LEWISVILLE, Texas, Sept. 7, 2016 /PRNewswire/ -- Adeptus Health Inc. (NYSE: ADPT), the largest operator of freestanding emergency rooms in the U.S., today announced that Thomas S. Hall has informed the Board of Directors of his intention to retire as Chief Executive Officer.  To ensure an orderly transition, Mr. Hall intends to continue as CEO until the earlier of mid-2017 or the appointment of his successor.  Mr. Hall has also agreed to remain on the Board as Chairman through his current term, which ends at the Company's 2017 Annual Meeting of Stockholders.
Sep 06, 2016 08:00 am ET
Adeptus Health Inc. to Present at the Morgan Stanley Global Healthcare Conference
LEWISVILLE, Texas, Sep. 6, 2016 /PRNewswire/ -- Adeptus Health Inc. (NYSE: ADPT), the largest operator of freestanding emergency rooms in the U.S., today announced that executives Thomas S. Hall, Chairman and CEO and Frank R. Williams, Jr., Executive Vice President and CFO, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York City on Monday, September 12, 2016 at 4:15 p.m. ET.
Jul 28, 2016 08:00 am ET
Adeptus Health Inc. Appoints Frank R. Williams, Jr. as Chief Financial Officer
LEWISVILLE, Texas, July 28, 2016 /PRNewswire/ -- Adeptus Health Inc. (NYSE: ADPT), the largest operator of freestanding emergency rooms in the U.S., today announced Frank R. Williams, Jr. will join Adeptus Health's executive leadership as Executive Vice President and Chief Financial Officer. Williams will succeed Timothy L. Fielding, who has decided to pursue other business interests.  Fielding will remain with the company through the end of September to ensure a smooth transition.
Jul 21, 2016 07:50 am ET
Adeptus Health Reports Second Quarter 2016 Results
LEWISVILLE, Texas, July 21, 2016 /PRNewswire/ -- Adeptus Health Inc. (NYSE: ADPT) ("ADPT" or the "Company"), the largest operator of freestanding emergency rooms in the U.S., announced its results for the second quarter ended June 30, 2016. All comparisons included in this release are for the same period in the prior year, unless otherwise noted. See "Non-GAAP Financial Measures Description and Reconciliation" for further information related to systemwide revenue, Adjusted EBITDA and Adjusted earnings per share.
Jul 14, 2016 08:00 am ET
Adeptus Health to Announce Second Quarter 2016 Financial Results
LEWISVILLE, Texas, July 14, 2016 /PRNewswire/ -- Adeptus Health Inc. (NYSE: ADPT), the largest operator of freestanding emergency rooms in the U.S., today announced that it will release its second quarter 2016 financial results pre-market on Thursday, July 21, 2016.
Jun 24, 2016 08:00 am ET
Adeptus Health Inc. Appoints Dr. Ricardo Martinez as Chief Medical Officer
LEWISVILLE, Texas, June 24, 2016 /PRNewswire/ -- Adeptus Health Inc. (NYSE: ADPT), the largest operator of freestanding emergency rooms in the U.S., today announced Ricardo Martinez, M.D. has joined the Adeptus Health team as Chief Medical Officer.
Jun 03, 2016 08:00 am ET
Adeptus Health Inc. to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
LEWISVILLE, Texas, June 3, 2016 /PRNewswire/ -- Adeptus Health Inc. (NYSE: ADPT), the largest operator of freestanding emergency rooms in the U.S., today announced that executives Thomas S. Hall, Chairman and CEO and Timothy Fielding, CFO will host a fireside chat at the Goldman Sachs 37th Annual Global Healthcare Conference in Ranchos Palos Verdes, California on Thursday, June 9, 2016 at 8:00 a.m. PDT / 11:00 a.m. EDT.  
Jun 02, 2016 09:45 pm ET
Adeptus Health Inc. Announces Pricing of Common Stock Offering
LEWISVILLE, Texas, June 2, 2016 /PRNewswire/ -- Adeptus Health Inc. (NYSE: ADPT) (the "Company" or "Adeptus Health") today announced the pricing of the previously announced offering of 2,450,000 shares of its Class A common stock, of which 1,543,162 shares are to be sold by the Company, and 906,838 shares are to be sold by an affiliate of Sterling Partners (the "Selling Stockholder"), at a price to the public of $62.00 per share. The Company intends to use all of the net proceeds from the offering received by it to purchase, for cash, 1,543,162 limited liability company units of Adeptus Heal
May 31, 2016 05:16 pm ET
Adeptus Health Inc. Announces Common Stock Offering
LEWISVILLE, Texas, May 31, 2016 /PRNewswire/ -- Adeptus Health Inc. (NYSE: ADPT) (the "Company" or "Adeptus Health") today announced the offering of 2,750,000 shares of its Class A common stock, of which 1,843,162 shares are to be sold by the Company, and 906,838 shares are to be sold by an affiliate of Sterling Partners (the "Selling Stockholder"). The Company intends to use all of the net proceeds from the offering received by it to purchase, for cash, 1,843,162 limited liability company units of Adeptus Health LLC, its direct subsidiary, from certain of the unit holders of Adeptus Health
May 31, 2016 05:14 pm ET
Adeptus Health Increases Full Year 2016 Guidance and Previews 2016 Second Quarter Results
LEWISVILLE, Texas, May 31, 2016 /PRNewswire/ -- Adeptus Health Inc. (NYSE: ADPT), the largest operator of freestanding emergency rooms in the U.S., today announced an update to its previously issued guidance for full year 2016. Adeptus Health expects full year 2016 systemwide net patient services revenue, which includes revenue from Adeptus Health's unconsolidated joint ventures, in a range of $640 million to $670 million, Adjusted EBITDA in a range of $110 million to $115 million and Adjusted earnings per share in a range of $2.55 to $2.65. In addition, Adeptus Health expects second quarter
May 11, 2016 07:45 am ET
Texas Health Resources and Adeptus Health Join Forces to Enhance Access to Emergency Care in North Texas
ARLINGTON, Texas and LEWISVILLE, Texas, May 11, 2016 /PRNewswire/ -- One of the country's largest non-profit health systems, Texas Health Resources, and the nation's leading operator of freestanding emergency rooms, Adeptus Health (NYSE: ADPT), today announced a joint venture to increase access to high quality, convenient emergency medical care in the Dallas-Fort Worth area.
May 02, 2016 09:30 am ET
Adeptus Health Inc. to Present at Bank of America Merrill Lynch 2016 Health Care Conference
LEWISVILLE, Texas, May 2, 2016 /PRNewswire/ -- Adeptus Health Inc. (NYSE: ADPT), the largest operator of freestanding emergency rooms in the U.S., today announced that executives Thomas S. Hall, Chairman and CEO, and Timothy Fielding, CFO, will present at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, Nevada on Tuesday, May 10, 2016 at 10:00 am PDT.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.